Analysis on NA gene characterization of influenza B virus Victoria lineage in Xinjiang

Abstract

Abstract:

Objective To analyze the NA gene evolution and variation characteristics of 14 strains of influenza B virus Victoria in Xinjiang，and to master its evolutionary characteristics and variation rules，so as to provide certain scientific basis for the prevention and control of influenza in Xinjiang. Methods According to the surveillance requirements of the National Influenza Surveillance Program（2017 edition），the specimen collection，virus isolation and identification，and strain submission for review were carried out. The NA genes of 14 strains of influenza B virus Victoria in Xinjiang from 2023 to 2024 were sequenced，and the genetic characteristics were analyzed by bioinformation software. Results The 14 strains of type B Victoria isolated from Xinjiang belonged to the V1A.3a2 branch of vaccine strain B/Austria/1359417/2021 published by WHO in the Northern hemisphere in 2023-2024. The genetic distance of NA gene from 14 Xinjiang B Victoria strains ranged from 0 to 0.012，and from vaccine strain B/Austria/1359417/2021 ranged from 0.007 to 0.010. The nucleotide homology of NA gene of 14 strains of influenza virus was 98.8%~100.0%，which was 99.0%-99.2% compared with vaccine strains. The amino acid homology of NA gene of 14 strains of influenza virus was 98.0%-100.0%，and the nucleotide homology was 98.2%-99.3% compared with vaccine strains. There were 13 substitutions at NA amino acid sites in 14 strains of influenza virus. Compared with previous vaccine strains，14 strains of influenza virus in Xinjiang share four glycosylation sites. Conclusions The Victoria strain of influenza B virus circulating in Xinjiang in the influenza surveillance year of 2023-2024 has high homology with the vaccine strain，indicating a high degree of matching with the vaccine strain. No mutation of drug resistance sites occurred，but the change of glycosylation sites still needs attention. Whether this change will affect the effect of NA inhibitors still needs further study.

Key words: Influenza B virus, Victoria lineage, NA gene

CLC Number:

R373.1⁺3

ZHANG Xuan, CHEN Yuan, HUANG Jia, LI Quanxi, Mirizhati Nuermaimaiti, MA Xin. Analysis on NA gene characterization of influenza B virus Victoria lineage in Xinjiang. [J]OCCUPATION AND HEALTH, 2026, 42(4): 470-475.

Figures/Tables 7

References 30

[1]	陈玲, 韩雪, 丛实. 2018—2022年辽宁省沈阳市季节性流感病毒行特征及乙型流感病毒分子进化分析[J]. 疾病监测, 2004, 39(5):609-615.
[2]	LI P, LIU X F, LANG Y M, et al. A comparative study of severe and critical influenza B in children in the 2021-2022 winter season[J]. Int J Gen Med, 2022,15:7995-8001.
[3]	MC CULLERS J A, HAYDEN F G. Fatal influenza B infections:time to reexamine influenza research priorities[J]. J Infect Dis, 2012, 205(6):870-872. DOI URL
[4]	FRANCIS T. A new type of virus from epidemic influenza[J]. Science, 1940, 92(2392):405-408. PMID
[5]	MA W J, GARCI-SASTRE A, SCHWEMMLE M. Expected and unexpected features of the newly discovered bat influenza A-like viruses[J]. PLoS Pathog, 2015, 11(6):e1004819. DOI URL
[6]	岳冬辉, 毕岩, 宋伍, 等. 清代医家雷少逸论治时病的贡献与特色探析[J]. 中华中医药杂志, 2018, 33(6):2534-2536.
[7]	岳冬辉, 高玉伟, 宫晓燕, 等. 扶正除疫颗粒抗甲型H1N1流感病毒感染作用评价[J]. 中医杂志, 2014, 55(23):2029-2033.
[8]	谭伟, 徐倩, 谢芝勋. 禽流感病毒研究概述[J]. 基因组学与应用生物学, 2014, 33(1):194-199.
[9]	HAYDEN F G, KAISER L, GUBAREVA L V. Influenza virus neuraminidase inhibitors.[J]. The Lancet, 2000, 355(9206):827-835. DOI URL
[10]	中华人民共和国国家卫生和计划生育委员会.全国流感监测方案(2017年版)[Z]. 北京: 国家卫生计生委办公厅, 2017.
[11]	FUJISAKI S, IMAI M, TAKASHITA E, et al. Mutations at the mono-mer-monnmer interface away from the active site of influenza B vi-rus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs[J]. J Infect Chemother, 2013, 19(5):891-895. DOI URL
[12]	SHEU T G, DEYDE V M, GARTEN R J, et al. Detection of antiviral re-sistance and genetic lineage markers in influenza B virus neuramin-idase using pyrosequencing[J]. Antiviral Res, 2010, 85(2):354-360. DOI URL
[13]	FERRARIS, LINA B. Mutations of neuraminidase implicated in neura-minidase inhibitors resistance[J]. J Clin Virol, 2008, 41(1):13-19. DOI URL
[14]	张艳燕, 赖宇, 朱琳, 等. 上饶市乙型流感病毒耐药基因分析[J]. 中国感染与化疗杂志, 2017, 17(5):538-540.
[15]	FLANNERY B, CHUNG J R, BELONGIA E A, et al. Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness-Unit-ed States,February 2018[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(6):180-185. DOI URL
[16]	SKOWRONSKI D M. Savedrecs[J]. Euro surveillance:bulletin eu ro Péen sur les maladies transmissibles, 2020, 25(7):2-8.
[17]	余钧, 陈柳军, 刘一. 2022—2023年柳州市B型流感病毒全基因组遗传特征分析[J]职业与健康, 2024, 40(21):2900-2908.
[18]	FANG Z C, TENG L, JIA G X, et al. Key amino acid residues of neu-raminidase involved in influenza a virus entry[J]. Pathog Dis, 2019, 77(6):1-9.
[19]	刘丽, 孙爱猛, 罗青, 等. 2016—2017 年吉安市乙型流感病毒基因特征分析[J]. 实验与检验医学, 2018, 36(6):833-835.
[20]	王莹丽, 蒋艳, 朱瑞芳, 等. 全球与中国流感病毒对 NAIs 耐药性趋势及特征[J]. 中华医院感染学杂志, 2020, 30(2):272-277.
[21]	EGLOFF A M, VELLA L A, FINN O J. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer[J]. Cancer Res, 2006, 66(1):6-9. DOI PMID
[22]	NAKAYAMA Y, YAMAGUCHI N. Role of cyclin B1 levels in DNA damage and DNA damage-induced senescence[J]. Int Rev Cell Mol Biol, 2013, 305(1):303-337.
[23]	陈宏彬, 张炎华, 林琦, 等. 2016 年福建省 B 型流感病毒基因特征分析[J]. 中国人兽共患病学报,2020, 36(2):118-123.
[24]	PETROVA V N, RUSSELL C A. The evolution of seasonal influenzaviruses[J]. Nat Rev Microbiol, 2018, 16(1):47-60. DOI URL
[25]	TROMBETTA C M, KISTNER O, MONTOMOLI E, et al. Influenza virusesand vaccines:the role of vaccine effectiveness studies forevaluation of the benefits of influenza vaccines[J]. Vaccines, 2022, 10(5):714. DOI URL
[26]	DO T H T, WILLE M, WHEATLEY A K, et al. Triton X-100-treated virus-based ELLA demonstrates discordant antigenic evolution of influenza B virus hemagglutinin and neuraminidase[J]. J Virol, 2024, 98(10):e0118624
[27]	COX N J, SUBBARAO K. Global epidemiology of influenza:Past and present[J]. Annu Rev Med, 2000,51:407-421.
[28]	WILEY D C, SKEHEL J J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus[J]. Annu Rev Biochem, 1987,56:365-394.
[29]	WATANABE Y, BOWDEN T A, WILSON I A, et al. Exploitation of glycosylation in enveloped virus pathobiology[J]. Biochim Biophys Acta Gen Subj, 2019, 1863(10):1480-1497. DOI URL
[30]	TAKASHITA E, KAWAKAMI C, OGAWA R, et al.Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected in Japan[J]. Euro Surveill, 2019, 24(12):1900170.

序号	毒株名称	序号
序号	毒株名称	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
1	B/Xingjiang/11149/2023
2	B/Xingjiang/174/2024	0.012
3	B/Xingjiang/116/2024	0.009	0.002
4	B/Xingjiang/11411/2023	0.009	0.002	<0.001
5	B/Xingjiang/134/2024	0.010	0.003	0.001	0.001
6	B/Xingjiang/169/2024	0.010	0.003	0.001	0.001	0.001
7	B/Xingjiang/14001/2024	0.009	0.002	<0.001	<0.001	0.001	0.001
8	B/Xingjiang/1720/2024	0.008	0.011	0.009	0.009	0.009	0.009	0.009
9	B/Xingjiang/16/2024	0.012	0.004	0.002	0.002	0.003	0.003	0.002	0.011
10	B/Xingjiang/187/2024	0.011	0.004	0.001	0.001	0.002	0.002	0.001	0.010	0.004
11	B/Xingjiang/111/2024	0.009	0.002	<0.001	<0.001	0.001	0.001	<0.001	0.009	0.002	0.001
12	B/Xingjiang/1123/2024	0.010	0.003	0.001	0.001	0.001	<0.001	0.001	0.009	0.003	0.002	0.001
13	B/Xingjiang/114/2024	0.012	0.004	0.002	0.002	0.003	0.003	0.002	0.011	0.004	0.004	0.002	0.003
14	B/Xingjiang/1470/2024	0.007	0.010	0.008	0.008	0.009	0.009	0.008	0.002	0.010	0.009	0.008	0.009	0.010
15	B/Austria/1359417/2021	0.009	0.010	0.008	0.008	0.009	0.009	0.008	0.008	0.010	0.009	0.008	0.009	0.010	0.007

序号	毒株名称	序号
序号	毒株名称	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
1	B/Xingjiang/11149/2023
2	B/Xingjiang/174/2024	0.012
3	B/Xingjiang/116/2024	0.009	0.002
4	B/Xingjiang/11411/2023	0.009	0.002	<0.001
5	B/Xingjiang/134/2024	0.010	0.003	0.001	0.001
6	B/Xingjiang/169/2024	0.010	0.003	0.001	0.001	0.001
7	B/Xingjiang/14001/2024	0.009	0.002	<0.001	<0.001	0.001	0.001
8	B/Xingjiang/1720/2024	0.008	0.011	0.009	0.009	0.009	0.009	0.009
9	B/Xingjiang/16/2024	0.012	0.004	0.002	0.002	0.003	0.003	0.002	0.011
10	B/Xingjiang/187/2024	0.011	0.004	0.001	0.001	0.002	0.002	0.001	0.010	0.004
11	B/Xingjiang/111/2024	0.009	0.002	<0.001	<0.001	0.001	0.001	<0.001	0.009	0.002	0.001
12	B/Xingjiang/1123/2024	0.010	0.003	0.001	0.001	0.001	<0.001	0.001	0.009	0.003	0.002	0.001
13	B/Xingjiang/114/2024	0.012	0.004	0.002	0.002	0.003	0.003	0.002	0.011	0.004	0.004	0.002	0.003
14	B/Xingjiang/1470/2024	0.007	0.010	0.008	0.008	0.009	0.009	0.008	0.002	0.010	0.009	0.008	0.009	0.010
15	B/Austria/1359417/2021	0.009	0.010	0.008	0.008	0.009	0.009	0.008	0.008	0.010	0.009	0.008	0.009	0.010	0.007

毒株号	糖基化位点
毒株号	56-58	64-66	144-146	284-286
B/Xinjiang/11149/2023	NAS	NRS	NGT	NKT
B/Xinjiang/174/2024	NAS	NLS	NGT	NKT
B/Xinjiang/116/2024	NAS	NRS	NGT	NKT
B/Xinjiang/11411/2023	NAS	NRS	NGT	NKT
B/Xinjiang/134/2024	NAS	NRS	NGT	NKT
B/Xinjiang/169/2024	NAS	NRS	NGT	NKT
B/Xinjiang/14001/2024	NAS	NRS	NGT	NKT
B/Xinjiang/1720/2024	NAS	NRS	NGT	NKT
B/Xinjiang/16/2024	NAS	NRS	NGT	NKT
B/Xinjiang/187/2024	NAS	NRS	NGT	NKT
B/Xinjiang/111/2024	NAS	NRS	NGT	NKT
B/Xinjiang/1123/2024	NAS	NRS	NGT	NKT
B/Xinjiang/114/2024	NAS	NRS	NGT	NKT
B/Xinjiang/1470/2024	NAS	NRS	NGT	NKT
B/Washington/02/2019	NAS	NRS	NGT	NKT
B/Austria/1359417/2021	NAS	NRS	NGT	NKT
B/Colorado/06/2017	NAS	NRS	NGT	NKT
B/Brisbane/60/2008	NAS	NRS	NGT	NKT

毒株号	糖基化位点
毒株号	56-58	64-66	144-146	284-286
B/Xinjiang/11149/2023	NAS	NRS	NGT	NKT
B/Xinjiang/174/2024	NAS	NLS	NGT	NKT
B/Xinjiang/116/2024	NAS	NRS	NGT	NKT
B/Xinjiang/11411/2023	NAS	NRS	NGT	NKT
B/Xinjiang/134/2024	NAS	NRS	NGT	NKT
B/Xinjiang/169/2024	NAS	NRS	NGT	NKT
B/Xinjiang/14001/2024	NAS	NRS	NGT	NKT
B/Xinjiang/1720/2024	NAS	NRS	NGT	NKT
B/Xinjiang/16/2024	NAS	NRS	NGT	NKT
B/Xinjiang/187/2024	NAS	NRS	NGT	NKT
B/Xinjiang/111/2024	NAS	NRS	NGT	NKT
B/Xinjiang/1123/2024	NAS	NRS	NGT	NKT
B/Xinjiang/114/2024	NAS	NRS	NGT	NKT
B/Xinjiang/1470/2024	NAS	NRS	NGT	NKT
B/Washington/02/2019	NAS	NRS	NGT	NKT
B/Austria/1359417/2021	NAS	NRS	NGT	NKT
B/Colorado/06/2017	NAS	NRS	NGT	NKT
B/Brisbane/60/2008	NAS	NRS	NGT	NKT